Persistent methicillin-resistant Staphylococcus aureus (MRSA) nares test positivity during initial days of systemic antistaphylococcal antimicrobial therapy - 30/12/24

Résumé |
The typical duration of positive nucleic acid tests for methicillin-resistant Staphylococcus aureus (MRSA) in the nares of patients receiving systemic anti-MRSA antimicrobials is unknown. In this study, hospitalized adult patients with an initial positive MRSA nares nucleic acid test prescribed systemic anti-MRSA antimicrobials had follow-up testing done 48 to 96 hours later. A positive follow-up test was detected in 100/113 (88.5%), indicating that MRSA nares DNA tests still have utility for screening after patients have initiated anti-MRSA therapy.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Methicillin resistant Staphylococcus aureus (MRSA) nares screening is central to stewardship. |
• | Optimizing and expanding this tool is important in reducing over-use of anti-MRSA agents. |
• | 100/113 MRSA nares samples remained positive after 2-3 days on anti-MRSA agents. |
• | MRSA nares screening remains clinically useful after 2-3 days on anti-MRSA therapy. |
Key Words : Antimicrobial stewardship, Colonization
Plan
| Conflicts of interest: Dr Asiago-Reddy has received funds from Pfizer, Theratechnologies, Glaxo-Smith-Kline (Viiv), and Abbvie for studies on which she is an investigator. None of the studies she has worked on with these entities was relevant to this project, nor did any of these entities contribute to the funding of this project. All other authors report no conflicts of interest. |
|
| Funding: The first author received a G.E.R.M. grant from the Infectious Disease Society of America (IDSA) to partially fund this work, and the senior author received start-up funding from their primary institution, at which the study took place. |
Vol 53 - N° 1
P. 154-156 - janvier 2025 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
